The overall goal of the Clinical Oncology Research Career Development Program is to support the intent of the Paul Calabresi Award for Clinical Oncology (K12). The Program fosters interdisciplinary training in clinical and translational oncology therapeutic research for physicians in one of a number of oncology disciplines, including medical, surgical, dermatologic, pediatric, radiation and pathology. By designing a K12 program that brings together these broad disciplines, the Paul Calabresi Scholars themselves form a multidisciplinary group whose collaborations and interactions augment the overall training efforts under the K12 program. Firm core requirements include completion of required and elective course work for a Certificate in Clinical Translational Oncology at CWRU. A basic research effort is a required part of the training program and is linked to the clinical research efforts that include writing and activating a therapeutic clinical protocol and submission of a career development award application. These efforts will result in highly qualified Paul Calabresi scholars capable of independent research in clinical oncology and therapeutics with a team science orientation based in hypothesis testing of important translational questions in the field. The Program brings together strong Internal and External Advisory Committees committed and experienced in the area of clinical translational therapeutics research in oncology. The Program and the cancer center provides scholars with an outstanding environment to pursue career development. Past trainees have emerged as academic physicians developing independent clinical research programs often with external funding and with active investigator-initiated clinical trial efforts.
This mentored career development program supports physician investigators to gain skills in cancer research and clinical therapeutics that emphasizes innovative treatments and use of genomics to select proper and individualized treatments for cancer patients, increasing the likelihood that such treatment will be effective.
|Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533|
|Saygin, Caner; Hirsch, Cassandra; Przychodzen, Bartlomiej et al. (2018) Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J 8:4|
|Ye, Rebecca; Tomlinson, Benjamin; de Lima, Marcos et al. (2018) Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia. Case Rep Hematol 2018:9807047|
|Stahl, Maximilian; DeVeaux, Michelle; de Witte, Theo et al. (2018) The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv 2:1765-1772|
|Conic, Ruzica Z; Arbesman, Joshua (2018) Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage. J Invest Dermatol 138:1218-1221|
|Rambhia, Pooja H; Honda, Kord; Arbesman, Joshua (2018) Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient. Melanoma Res 28:475-477|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Pan, Feng; Wingo, Thomas S; Zhao, Zhigang et al. (2017) Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun 8:15102|
|Doherty, Mary R; Cheon, HyeonJoo; Junk, Damian J et al. (2017) Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A 114:13792-13797|
|Negoro, Eiju; Nagata, Yasunobu; Clemente, Michael J et al. (2017) Origins of myelodysplastic syndromes after aplastic anemia. Blood 130:1953-1957|
Showing the most recent 10 out of 88 publications